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Abstract 
Objective: HIV-1 frequently adapts in response to immune pressure from cytotoxic T-
lymphocytes (CTL).Many HIV-2 infected individuals have robust capsid-specific CTL responses 
associated with viral control. Despite this CTL pressure, adaptive changes in this key 
immunogenic HIV-2 protein have not previously been described. We sought to compare 
selective pressure on HIV-1 and HIV-2 capsids and identify HLA-associated viral 
polymorphisms in HIV-2.  
Design and methods: Bioinformatic algorithms to identify sites under positive and negative 
selective pressure and a statistical model of evolution to identify HLA-associated polymorphisms 
in HIV-2 was applied to sequences from a community cohort in Guinea-Bissau. IFN- ELISpots 
were used to compare T-cell responses to wild-type and variant epitopes. 
Results:We identified greater purifying selection and less sites under positive selective pressure 
in HIV-2 compared to HIV-1. Five HIV-2 codons with HLA-associated polymorphisms were 
detected all within or around known or predicted CTL epitopes. One site was within theHLA-B58 
SuperType (ST)-restricted epitope (TSTVEEQIQW), the HIV-2 equivalent of the HIV-1 TW10 
epitope. In contrast to HIV-1, where a T→N mutation at position 3 is associated with resulting 
loss of CTL control, an E→D mutation at position 5was observed in HIV-2. Robust CTL 
responses to the variantHIV-2 epitope were seen, suggesting that HIV-2 adaptation may be at the 
level of T-cell receptor recognition.  
Conclusions:Greater constraints on evolution may exist in HIV-2, resultinginmore purifying 
selection and different immune adaptation pathways in HIV-1 and HIV-2 capsids. This may 
allow CTL responses to persist in HIV-2. 
Key words: HIV-2, HLA, cytotoxic T-lymphocyte 
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Introduction 
HIV-specific cytotoxic T-lymphocyte (CTL) responses are thought to play an important role in 
HIV-1 control[1-4]. A hallmark of HIV-1 evolution however, isthe rapid appearance of mutations 
within CTL epitopes, leading to loss of CTL recognition and immune control[5]. HIV-2 differs 
from HIV-1 in that a substantial proportion of infected people maintain undetectable plasma viral 
loads (VLs) for decades with no signs of immunodeficiency.Many others have VLs 30-fold 
lower than HIV-1 at equivalent disease stages[6-9].We have previously demonstrated a strong 
correlation between the presence of high frequency HIV-2 Gag-specific CTLs and viral 
control[10-12]. As HIV-2 is able to generate resistance mutations akin to HIV-1 under 
antiretroviral pressure[13], HIV-2 should also have the capacity to adapt to immune responses 
similar to HIV-1.  
Establishing similarities and differences between HIV-1 and HIV-2 immune evasion strategies 
has the potential to enhance our understanding of HIV pathogenesis. HIV-1 p24 and HIV-2 p26 
represent the two major CTL-targeted proteins in these viruses. Here, we provide the first 
comparison of selective pressure in HIV-1 p24 and HIV-2 p26 capsid sequences from a 
community cohort in Guinea-Bissau, along with HLA-associated viral polymorphisms in HIV-
2,which may represent CTL-driven adaptive changes.  
Methods 
Study participants 
Antiretroviral therapy (ART)-naïve HIV-1 and HIV-2 mono-infected subjects from Caió, 
Guinea-Bissau were recruited following written informed consent during serosurveys and case-
control studies conducted in thisrural community cohort over almost three decades[14]. CD4 and 
HIV-2 plasma VL quantification(using an in-house RT-PCR assay) were performed as 
previously described[7,12].VLs were available in 75/86 and CD4+ counts in 72/86 of HIV-2-
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infected individuals. Median (range) VL was 275 (<100-283,542) and CD4+ T-cell count 
547.5/mm3(100-1705). 30/75 (40%) had a VL of <100 copies/ml, which is broadly reflective of 
the wider cohort[15]. HLA class I genotyping on HIV-2-infected subjects was performed during a 
previous study using sequencing[16,17]. Ethical approval was provided by the joint MRC/Gambia 
Government Ethics Committee, Guinea-Bissau Ministry of Health and the Oxford Tropical 
Research Ethics Committee (OXTREC), UK. 
Amplification and sequencing of HIV-1 and HIV-2 capsid  
Plasma samples from 55CRF02_AG HIV-1-infected subjects were used to generate p24 capsid 
sequences using previously described methods[18](supplementary methods, 
http://links.lww.com/QAD/B217). 86 HIV-2 p26 capsid sequences were used in this study: 
85previouslygenerated sequences (GenBank accession numbers GQ485448 – GQ485550 and 
JX570541 – JX570562) and1 new sequence generatedusing the same methodology[19].  
Sequence analysis and tests for codon selection 
Sites under positive and negative selection in HIV-1 (231 codons) and HIV-2 (230 codons) were 
identified by comparison of synonymous (dS,no amino acid change) and non-synonymous 
(dN,amino acid change) substitution rates using three different methods in the Datamonkey web-
server[20]: single-likelihood ancestor counting (SLAC), fixed-effects likelihood (FEL) and fast 
unbiased Bayesian approximation (FUBAR)[21,22](supplementary methods, 
http://links.lww.com/QAD/B217). A p-value cut-off of 0.05 (SLAC and FEL) and posterior 
probability of 0.95 (FUBAR) was used to define significant positive or negative selection at a 
codon. 
Identification of HLA-associated HIV-2 viral polymorphisms 
HLA-associated HIV-2 viral polymorphisms were identified using a phylogenetically-corrected 
logistic regression, used extensively for identifying HLA-associated HIV-1  viral 
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polymorphisms[23]. This method corrects for phylogenic relatedness, HLA-linkage disequilibrium 
and codon covariation. Class I HLA types from 73 HIV-2-infected adults were available for this 
analysis. Separate statistical tests were constructed for each HLA-amino acid pair, limited to HLA 
alleles and amino acids that were observed in at least five and at most 68 subjects. To correct for 
multiple comparisons, we used a 20% false discovery rate (threshold p<0.0008). Epitope 
predictions were made by scanning the candidate sequence for peptides of 8 – 11 amino acids, 
with each prediction made using the supplied HLA (2% prior probability distribution). 
IFN-ELISpot 
Cryopreserved peripheral blood mononuclear cells (PBMCs) from HIV-2-infected patients were 
usedin ex vivo IFN-γ enzyme-linked immunosorbent spot (ELISpot) assays as previously 
described[12], to quantify responses to wild type and variant epitopes (supplementary methods, 
http://links.lww.com/QAD/B217).  
Results 
Fewer adaptive changes are present in HIV-2 p26compared to HIV-1 p24 
Using three different algorithms[21,22], we evaluated selective pressure evident across the HIV-1 
p24and HIV-2 p26 capsids. In all analyses, there were more sites under positive selective 
pressure in HIV-1 p24 (6 vs 2 in SLAC, 8 vs 2 in FELand 12 vs 2 in FUBARanalysis) and more 
sites under negative selective pressure in HIV-2 p26 (139 vs 61 in SLAC, 157 vs 82 in FEL and 
151 vs 131 in FUBAR analysis); Chi-squared p <0.0001, p <0.0001 and p = 0.0096 respectively 
for the three algorithms.A significantly higher mean dN/dS ratio (95% confidence interval) of 
0.249 (0.223 – 0.277) in HIV-1 compared to 0.099 (0.099 – 0.110) in HIV-2 (p <0.0001) 
confirmed the greater purifying selection seen in HIV-2 (i.e. selectivepurging of deleterious 
alleles).  
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We further characterized the sites under positive selective pressure in HIV-1 p24 and HIV-2 p26 
(Figure 1, Supplementary Tables 1 and 2, http://links.lww.com/QAD/B217). The two sites under 
positive selection in HIV-2 (identified by all three algorithms)are not within anyknown HIV-2 
CTL epitope regions, although are in regions flankingB*35 and B*14-restricted epitopes 
respectively (Figure 1). Changes in flanking residues can affect epitope processing and 
presentation, therefore influencing CTL response[24].  
Three of thefour currentlyknown HIV-2 CTL epitopes (restricted by HLA-B*14, B*3501, 
B*5301[12])were conserved in 96.4%, 82.6% and 97.7% of HIV-2 sequences respectively, despite 
robust ELISpot responses against these epitopes in HLA-B*14, B*3501 and B*5301-positive 
individuals (Supplementary Table 3, http://links.lww.com/QAD/B217). This may indicate 
constraints against evolution within these epitopes, thereby forcing evolutionary change in 
flanking regions.In contrast, all six HIV-1 p24 sites under positive selective pressure (identified 
by all three algorithms)lie withinputative CTL epitopes restricted by HLA alleles common in 
Caió (Supplementary Table 3, http://links.lww.com/QAD/B217), including the well described 
T242N mutation in the HLA-B*57/B*5801-restricted TW10 epitope (TSTLQEQIGW)[25,26].  
Identification of a potential HLA-associated HIV-2 p26 polymorphism within a known HLA-
B*5801-restricted CTL epitope 
We then identifiedfive associations between HLA alleles and polymorphisms in HIV-2 p26 using 
a previously described statistical model[23](Table 1). Position 254 (associated with HLA-B*35) is 
immediately upstream of the HLA-B*3501-restricted epitope NPVPVGNIY and position 245 
(associated with HLA-B58ST) lies within the known B*57/B*5801-restricted TW10-like HIV-2 
epitope TSTVEEQIQW (Figure 1). Positions 256, 294 and 313 were all within or in regions 
flanking predicted epitopes restricted by the identified HLA types (Table 1).The glutamic acid 
(E) to aspartic acid (D) change at position 245was observed in 65% ofHLA-B58 ST-positive 
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compared to 32% ofHLA-B58 ST-negative individuals. No HIV-2 sequences had evidence of the 
HIV-1 equivalent T→N mutation at position 3 (i.e. T242N).  
Robust T-cell responses to the HIV-2 TW10-like wildtype and mutant epitopes despite the 
presence of the E245D polymorphism in HLA B*5801-positive individuals 
T242N escapewithin the HIV-1 TW10 epitope occurs early after infection, impacts HLA binding, 
leading to loss of CTL recognition and carries a fitness cost overcome by compensatory 
mutations[25,26]. As robust CTL responses are found in HIV-2-infected individuals decades after 
infection[10,12], we examined IFN- ELISpot responses to both wildtype HIV-2 (TSTVEEQIQW) 
and E245D variant (TSTVDEQIQW) peptides. ELISpot responses to both peptide variants were 
observed in almost all individuals (Supplementary Table 4, http://links.lww.com/QAD/B217), 
including robustresponses to the E245D mutant peptide. In all but one individual, the response 
was stronger against the peptide that matched the individual’s autologous virus sequence, 
suggesting that the T-cell response in these individuals could adapt to overcome this particular 
CTL epitopepolymorphism in HIV-2. In three donors where sufficient PBMCs were available to 
test, none had cross-reactive responses to HIV-1 TW10 (Supplementary Table 4, 
http://links.lww.com/QAD/B217). 
Discussion 
Wereport the first analysis of HLA-associated viral polymorphisms inHIV-2 p26, including a 
codon substitutionwithin a known immunodominantHLA-B*5801-restricted epitope. Thismay 
representCTL-driven adaptation by HIV-2 and allowsdirect comparison with what is known 
about the equivalent HLA-B57/B*5801-restricted epitope in HIV-1. In contrast to HIV-1, where a 
mutation at position 3 of the epitope (T242N) occurs in 63 - 93% of HLA-B*5801-positive 
individuals[25], a mutation at position 5 (E245D) is found in 65% of HLA-B58 STpositive 
patients.The HIV-1 TW10 epitope lies within a region essential for capsid formation[27] 
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andresidue 242 is thought to be critical to stabilizing the electrostatic charge along helix 6[26]. A 
T242N mutation reduces this stabilizing effect[26], consistent with viable virus with 
significantlyreduced fitness.It is possible that for HIV-2, with much lower in vivo viral titres than 
HIV-1, the fitness costs of such a mutation are too severe, leading to an alternative pathway of 
immune adaptation. Further functional studies are required to explore this hypothesis.  
The E→D mutation found in HIV-2 replaces one hydrophilic, negatively charged, amino acid 
with another. In contrast to HIV-1 where T242N escape usually results in loss of immune 
control, robust CTL responses are generated against this HIV-2 mutant. The absence of E245D 
mutant responses in one participant(B58_8, Supplementary Table 4, 
http://links.lww.com/QAD/B217) suggests thatthese E245D variant responsesdo not simply 
represent cross-reactive CTLs. The presence of CTLs specific to both variants in most 
individuals may reflect low-level persistence of epitope variants in the viral population not 
detected by bulk PCR sequencing used in this study. These data also imply that this potential 
HIV-2 immune adaptation is at the level of T-cell receptor recognition of the peptide-MHC 
complex, as peptide processing and MHC-epitope binding of E245D variants are presumably still 
maintained. 
We also describe the first comparison of selective pressure on HIV-1 and HIV-2 capsids, finding 
greater purifying selective pressurein HIV-2.We reported similarfindings in HIV-2env, where 
relative conservation of this highly variable gene is seen despite high magnitude autologous 
neutralizing antibody titres[28]. While one explanation for the lower adaptive changes in HIV-2 is 
lower viral replication compared to HIV-1, previous studies have demonstrated that evolutionary 
rates are equivalent if not faster in advanced HIV-2 than in HIV-1 infection[29]. Furthermore, the 
emergence of ART-driven resistance mutations in HIV-2 shows that at least in the reverse 
transcriptase and protease genes, viral escape can readily occur[13]. 
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A key limitation of our study is the lack of longitudinal data following individual patients from 
acute HIV-2 infection to demonstrate CTL-driven escape, shown extensively in HIV-1[1-5]. While 
such a study would add considerable insight, the reducing incidence of HIV-2 infection in West 
Africa, on a background of vastly lower transmission rates than HIV-1, makes this 
challenging[14,30]. Acute HIV-2 infection is difficult to identify and therefore rarely described. As 
an indirect way of investigating the issue of HIV-2 immune adaptation, we have therefore 
utilized a statistical model of evolution, well-validated in HIV-1 cohorts[23,31]. The significant 
proportion of HIV-2-infected individuals with low VLs make generating sequence data 
challenging (approximately 50% success if VL <100 copies/ml[19]) and could lead to a biased 
dataset when compared to HIV-1. Nevertheless, our dataset represents the largest collection of 
sequence data generated from HIV-2-infected individuals with VL <100 copies/ml to date[19]. 
Conclusions 
In conclusion, we provide the first evidence ofadaptive changes in the HIV-2 capsid. Our data 
highlight fundamental differences in immune adaptation between HIV-1 and HIV-2, suggesting 
that HIV-2 evolution may be limited in this region. Further functional studies are required to 
characterize the polymorphisms identified in HIV-2, validate our findings andexplore whether 
this characteristic explains why robust immune responses can persist in HIV-2-infected 
individuals for many years. This in turnmay underpin the diverse outcomes seen in HIV-1 and 
HIV-2 infections, providing a crucial clue to the yet unsolved conundrum of the relatively 
attenuated nature of most HIV-2 infections.  
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Position     140                160                 180                 200 
HIV-2 ROD  P-
VQHVGGNYTHIPLSPRTLNAWVKLVEEKKFGAEVVPGFQALSEGCTPYDINQMLNCVGDHQAAMQIIREIINEEAAEW 
             B53 
 
Position            140                 160                 180          200 
HIV-1 HXB2
 PIVQNIQGQMVHQAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQDLNTMLNTVGGHQAAMQMLKETINEEAAEW 
     
      
 
Position     220                  240                 260                 280 
HIV-2 ROD  DVQHPI-
PGPLPAGQLREPRGSDIAGTTSTVEEQIQWMFRPQNPVPVGNIYRRWIQIGLQKCVRMYNPTNILDIKQGPKE 
        B57/B58*01  B35 
 
Position            220                 240                  260                 280     
HIV-1 HXB2 DRVHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIGWMTN-NPPIPVGEIYKRWIILGLNKIVRMYSPTSILDIRQGPKE 
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Position  300                 320 340                 360 
HIV-2 ROD 
 PFQSYVDRFYKSLRAEQTDPAVKNWMTQTLLVQNANPDCKLVLKGLGMNPTLEEMLTACQGVGGPGQKARLM 
    B14 
 
Position             300                 320                 340                 360 
HIV-1 HXB2PFRDYVDRFYKTLRAEQASQEVKNWMTETLLVQNANPDCKTILKALGPAATLEEMMTACQGVGGPGHKARVL 
 
 
 
Figure 1. Alignment of HIV-2 ROD (M15390) and HIV-1 HXB2 (K03455) capsid sequences highlighting amino acid positions under 
positive selection in the Caió population.Sites under significant positive selection in HIV-1 CRF02_AG (n = 6, identified by all four 
algorithms SLAC, FEL, FUBAR and REL) and HIV-2 group A (n = 2, identified by all three algorithms SLAC, FEL and FUBAR) capsids are 
highlighted by grey shading.REL was not performed on the HIV-2 set due to alignment size restrictions. Numbering corresponds to Gag 
positions in ROD and HXB2. Known cytotoxic T-lymphocyte epitopes in the HIV-2 p26 capsid restricted by HLA Class I B alleles (common in 
the Caió population) are underlined.
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 Tables 
Table 1. Potential sites of HLA-mediated selection pressure and codon 
evolution in HIV-2 p26 as predicted by a phylogenetic 
dependency network analysis. 
 
HIV-2 
Gag 
codon  
Amino 
acid 
HLA 
association 
Direction* p-value 
q-
value‡ 
Predicted epitope 
around codon 
associated with 
relevant HLA type^^
Prediction 
probability 
(%) 
245 D B58_ST^ Adapted 0.0002 0.0684 STVDEQIQW‡‡ 94 
245 E B58_ST 
Non-
adapted 6.73E-05 0.0309 
STVEEQIQW‡‡ 92 
254 A B35 
Non-
adapted 0.0002 0.1030 
FRAQNPVPVGNIY
RRW‡‡‡ 
71 
254 P B35 Adapted 
0.0001 0.0336 
FRPQNPVPVGNIY
RRW‡‡‡ 
71 
254 P C08 Adapted 8.89E-05 0.0336 WMFRPQNPVPV 53 
256 V A03_ST^ Adapted 0.000749 0.1721 NPVPVGNIYRR 51 
256 I A03_ST 
Non-
adapted 0.000749 0.1721 
NPIPVGNIYRR 57 
294 S C0401 
Non-
adapted 2.79E-07 0.0002 
ESFQSYVDRFYKS
LRA 
60 
294 P C0401 Adapted 
1.10E-07 
8.32E-
05 
EPFQSYVDRFYKS
LRA 
60 
313 A B5801 Adapted 
4.93E-08 
5.66E-
05 
QTDAAVKNW 66 
313 P B5801 
Non-
adapted 1.79E-10 
4.11E-
07 
QTDPAVKNW 65 
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 ^ ST = SuperType (15).  
*Adapted = reported amino acid is the putative adaption at that site (i.e.‘escaped’ 
variant). Non-adapted = reported amino acid is putatively susceptible to escape (i.e. 
‘reversion’).  
‡Estimation of false-discovery rate for each association. i.e. q value of 0.05 = 5% 
false discovery rate 
^^Where codon is in flanking region, epitope is underlined. Codon is shown in 
bold. Epitope predictions are made by scanning the candidate sequence for peptide 
lengths of 8 – 11 amino acids. Only peptides within 3 amino acids of the associated 
codon are considered.  
‡‡ The 10-mer TSTVEEQIQW has been previously identified as a B58_ST-
restricted epitope via functional assays. The prediction algorithm used identifies 
the 9-mer STVDEQIQW as an optimal B58_ST-restricted epitope. 
‡‡‡NPVPVGNIY is a known B*35-restricted epitope 
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